Ubidecarenone
Alternative Names: Bio-Quinone Q10; Coenzyme Q10; CoQ10; Neuquinon; Q-Gel; UbiQGel; Ubiquinone; Vitaline; Vitaline CoQ10Latest Information Update: 07 Jan 2022
At a glance
- Originator Eisai Co Ltd; Enzymatic Therapy; Nonindustrial source; Pharma Nord; Tishcon Corporation
- Developer Enzymatic Therapy; Pharma Nord; Tishcon Corporation
- Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
- Mechanism of Action Antioxidants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Heart failure
- Discontinued Fibromyalgia; Huntington's disease; Immunodeficiency disorders; Metabolic disorders; Myocardial infarction; Neurological disorders; Parkinson's disease; Reperfusion injury; Stroke
Most Recent Events
- 19 Apr 2006 Phase-I clinical trials in Neurological disorders in USA (PO)
- 19 Apr 2006 Data presented at the 58th Annual Meeting of the American Academy of Neurology (AAN-2006) have been added to the adverse events and Neurological disorders therapeutic trials sections
- 22 Jun 2004 A study has been added to the adverse events and Heart Failure therapeutic trials sections